2019/04/09MEDICAL UPDATE

ECCO 2019: Translational science in IBD

Translational research is playing an increasingly vital role for bridging the gap between, on the one hand, basic science and on the other, clinical studies and routine clinical practice. Among the findings presented in a digital oral presentation session at ECCO 2019 were new insights into the mechanism of action of vedolizumab and potential new therapeutic targets for treating fibrosis and strictures in IBD... Interviewer: Hannah Chatfield, Author: Maria Dalby

READ MORE

2019/04/09MEDICAL UPDATE

ECCO 2019: IBD around the world

IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation... Interviewer: Hannah Chatfield, Author: Maria Dalby

READ MORE

2019/03/13MEDICAL UPDATE

ECCO 2019: Metabolic profiling

Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to finding new disease markers and targets for intervention. Interviewer: Hannah Chatfield, Author: Maria Dalby

READ MORE

2019/03/13MEDICAL UPDATE

ECCO 2019: VARSITY: head to head comparison of adalimumab vs vedolizumab in UC

The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab. More head-to-head trials are due to be completed shortly and the results are expected to be as important for clinical practice as the SONIC, CALM and NOR-SWITCH studies. Interviewer: Hannah Chatfield, Author: Maria Dalby

READ MORE

2019/03/11MEDICAL UPDATE

ECCO 2019 Highlights

The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber (Germany), Professor David Rubin (USA), Dr Filip Baert (Belgium) and Professor William Sandborn (USA) discuss their highlights from the meeting including the long-awaited head to head VARSITY study comparing adalimumab with vedolizumab and the maintenance data from the UNIFI study for ustekinumab. 

READ MORE

2019/02/14MEDICAL UPDATE

Highlights from ASH 2018

by Esther Drain As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study, which compared BV+CHP vs CHOP for patients with peripheral T-cell lymphoma. In the video above, Dr Graham Collins (Oxford, UK), Dr Alison J. Moskowitz (New York, USA) and Professor Andrei Shustov (Seattle, USA) provide their highlights from the meeting.

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

By Tom Collins (author) and Hannah Chatfield (interviews) Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on risk stratification of patients...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Advances in the management of peripheral T-cell lymphoma

By Maria Dalby (article) and Esther Drain (interviews) Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is therefore urgent...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Follicular Lymphoma: Have We Made Progress?

by Tom Collins (author) and Hannah Chatfield (interview) Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin lymphomas1 and although rarely curable, a number of treatment options exist. In an education session on current and emerging options for the treatment of FL, respectively, presentations focused on data supporting rituximab as single-agent or in combination with chemotherapy and as maintenance therapy in newly-diagnosed FL, and chemotherapy-free regimens and novel immunotherapy approaches in relapsed FL...

READ MORE

2019/02/05MEDICAL UPDATE

ASH 2018: Phoenix and other DLBCL study updates

by Tom Collins (article) and Esther Drain (interview) Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future plans following this study

READ MORE